e-Article – 부산대학교 도서관

e-Article

replayBack to search results

searchSearch screen

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial

Document Type

Article

Author

Molina, J.-M.; Rizzardini, G.; Orrell, C.; Afani, A.; Calmy, A.; Oka, S.; Hinestrosa, F.; Kumar, P.; Tebas, P.; Walmsley, S.; Grandhi, A.; Klopfer, S.; Gendrano, I.; Eves, K.; Correll, T.A.; Fox, M.C.; Kim, J.

Source

In: The Lancet HIV. (The Lancet HIV, June 2024, 11(6):e369-e379)

Subject

Language

English

ISSN

23523018

Online Access

Full Text (ScienceDirect 종량제) Full Text (Clinical Key) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일